Letter to the Editor: Commending the Feasibility of CYP2C19 Pharmacogenetic Testing in Personalized Antiplatelet Therapy—Insights and Perspectives

Key Points

• CYP2C19 pharmacogenetic testing enhances antiplatelet therapy outcome, impacting patient safety.
• Key evidence shows improved response rates among patients undergoing personalized treatment strategies.
• Observational insights on testing demonstrate the potential for tailored approaches in clinical practice.
• Highlights the importance of integrating pharmacogenetic markers for optimizing therapeutic decisions in various populations.